Regarding a decision of the Supervision Service of the Bank

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
98
Regarding a decision of the Supervision Service of the Bank of Lithuania

Telsiai, Lithuania, 2017-02-10 17:00 CET (GLOBE NEWSWIRE) -- On 10 February 2017, AB ŽEMAITIJOS PIENAS (the “Company”) received Decision No. 241-17 of the Director of the Supervision Service of the Bank of Lithuania “Regarding imposition of a measure of impact on the company” (the “Decision”). By the Decision the Company was, inter alia, obligated to make it public, indicating that:

1. By the Decision of the Director of the Supervision Service of the Bank of Lithuania, the Company was warned about violation of Article 22 of the Law of the Republic of Lithuania on Securities.

2. In the opinion of the Supervision Service of the Bank of Lithuania, financial statements of the Company for 2015 do not meet requirements of IAS 2 “Inventories”, IAS 16 “Property, Plant and Equipment” and IAS 39 “Financial Instruments: Recognition and Measurement”.

3. The impact of the violations on the financial statements is as follows:

3.1. As the Company did not assess, as on 31 December 2015, the current value of amounts receivable from related persons – AB Klaipėdos Pienas and AB Žemaitijos Pieno Investicija in the amount of EUR 3.612 million, of future cash flows discounted at the initial actual interest rate on such financial assets, it is impossible to establish the exact impact on the financial condition and financial results of the Company and the group. However, taking into account that impairment of all amounts receivable from related companies was recognised, which was not reasonable, it should be considered that, upon evaluation of the current value of the amounts receivable from related companies, the assets and the net result of the Company and the group for 2015 would increase.

3.2. As the Company did not substantiate, as on 31 December 2015, impairment of the inventories (fermented cheese in the aging process) of the Company and the group (EUR 4.366 million and EUR 4.676 million, respectively), it is impossible to accurately establish the impact on the financial condition and financial results of the Company and the group. However if, at the end of 2015, the net realisable value of inventories (fermented cheese in the aging process) of the Company and the group, which was not substantiated by the Company, were established to be different from that established by the Company, then the value of inventories of the Company and the group, as on 31 December 2015, could be more or less than indicated in the financial statements for 2015.

3.3. Taking into account that the period of useful life of fixed tangible assets, which are fully depreciated, but are still used in operations, was set shorter than usefulness of the assets for the economic entity (the Company and the group), expenses of the Company and the group for previous periods were increased and the value of assets was reduced.

4. Financial statements will be corrected retrospectively and forwards, assessed and published together with the audited financial statements of the Company for 2016, unless the Company decided to file a complaint against the Decision in court, as indicated below.

The Company also notes that the Decision presents the opinion of the Bank of Lithuania on the issues discussed above, in connection with the financial statements of the Company for 2015, which does not necessarily coincide with the position of the Company. After the management of the Company analyses the Decision and in case it does not agree to the position of the Bank of Lithuania stated therein, it will consider a possibility to complain against the Decision in court under the procedure set by applicable legal acts.

         Lawyer          G. Keliauskas          + 370 444 22208

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 34

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 37

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 39

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 122

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 280

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 75

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 111

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

Luckbox Stock Reaches New Low: Market Movements Explained

Updated Category News Views 326

Luckbox Stock Performance Overview The gaming and esports betting company, Luckbox, is currently navigating a fluctuating market landscape, with its stock price recently dipping to a notable 52-week low of $9.68. This shift is a pronounced departure from the previous year, reflecting ongoing challenges within the industry. As of now, the company's market capitalization...

Continue Reading
Nota AI and Renesas: Revolutionizing Driver Monitoring Technology

Updated Category News Views 153

Collaboration Between Nota AI and Renesas Nota AI, known for its expertise in AI optimization, has announced an exciting partnership with Renesas Electronics Corporation, aiming to advance driver monitoring technology through the optimized Driver Monitoring System (DMS). This collaboration is particularly focused on the new RA8P1 microcontroller unit (MCU), which is...

Continue Reading
Mirum Pharmaceuticals Presents Promising LIVMARLI Data at Conference

Updated Category News Views 107

Mirum Pharmaceuticals showcases LIVMARLI research findings Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...

Continue Reading
Genmab Stock Faces Challenges, Yet Holds Hope for Recovery

Updated Category News Views 130

Genmab Stock Overview Genmab A/S Sponsored ADR (NASDAQ: GMAB) has recently experienced a turbulent period, with a notable decline of 14.7% in just four weeks. However, this decline has left the stock in an oversold position, igniting hope among investors as analysts anticipate improved earnings results. Understanding Oversold Conditions To assess whether a stock, such as...

Continue Reading
Challenges Ahead for Central Banks Tackling Inflation Variability

Updated Category News Views 117

Challenges Ahead for Central Banks in Addressing Inflation Fluctuations Inflation is a complex issue for policymakers, as recent comments from European Central Bank President Christine Lagarde illustrate. With substantial changes happening in the global economy, the prospect of stable inflation remains uncertain. Lagarde suggests that inflation may experience significant...

Continue Reading